FDA approves APP Pharmaceuticals' generic infection drug

01/17/2008 | Forbes

APP Pharmaceuticals on Thursday announced that the FDA has cleared its polymyxin B sulfate injection, which is indicated for infections caused by pseudomonous aeruginosa. The drug, a generic version of Bedford Laboratories' Polymyxin B Sulfate, is expected to be on the market in the first quarter of the year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA